Cynthia Pussinen has officially filed a Form 3 with the SEC, confirming her position as the Chief Executive Officer and director of Estrella Immunopharma, Inc. This filing is significant as it underscores her leadership role within the company, particularly in the biological products sector.

Background

Estrella Immunopharma, Inc. operates in the biological products industry, specifically classified under the SIC code 2836. The company is listed under the Central Index Key (CIK) 0001844417. Recent filings indicate that the company has undergone a name change from TradeUP Acquisition Corp. on February 4, 2021. The firm is based in Emeryville, California, with its business address at 5858 Horton Street, Suite 370.

What the Filing Says

The Form 3 filing, dated November 3, 2026, states that Pussinen holds the role of CEO and director. The filing notes, "No securities in ESLA of any kind are beneficially owned," which indicates that Pussinen does not currently own shares in Estrella Immunopharma.

Impact

This filing may have implications for various stakeholders, including investors and employees, as it reinforces Pussinen’s leadership role in the company. Her position as CEO could influence strategic decisions and operational direction, potentially impacting the company's performance in the competitive biological products industry.

What's Next

The filing does not say what happens next.